Human Cancer Drugs May Be Effective in Tasmanian Devils

A new study reveals similarities between the transmissible cancers that infect the endangered marsupials, and hints at ways to treat them.

Written byShawna Williams
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

a Tasmanian devilMAXIMILIAN STAMMNITZFor Tasmanian devils, fighting brings a double jeopardy: survive the initial wound of a bite to the face and you may find yourself with a fatal tumor down the road. That’s because the endangered marsupials are one of just a handful of species known to get cancers that are contagious. Two of the eight known types transmissible cancers affect Tasmanian devils, and they now threaten the survival of the species. In a study published today (April 9) in Cancer Cell, researchers report similar mutation patterns between the two diseases, as well was potential treatments.

“When the first one was discovered, we thought that transmissible cancers were extremely rare and that Tasmanian devils were just really unlucky to get this cancer,” says study coauthor Elizabeth Murchison, a geneticist at the University of Cambridge, in a statement. “But the emergence of the second one made us wonder whether Tasmanian devils might be particularly at risk for developing this kind of disease.”

To find out, Murchison and her colleagues took a closer look at the molecular features of the two cancers, and found similar patterns of mutation and tissues of origin for both. The similarities suggest that Tasmanian devils have features that make them particularly vulnerable to transmissible cancers, Murchison says—including, perhaps, their biting behavior. The researchers also screened more than 100 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform